The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Incyte; Ipsen; Janssen; Janssen; Lilly; Pfizer; Pharmacyclics; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Endocyte (Inst); Genentech (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi
 
Xin Gao
Consulting or Advisory Role - Dendreon
Research Funding - Arvinas (Inst); Exelixis (Inst)
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Mary Harlow Garfield
Employment - Arvinas
Stock and Other Ownership Interests - Arvinas
Travel, Accommodations, Expenses - Arvinas
 
Ian Taylor
Employment - Arvinas
Leadership - Arvinas
Stock and Other Ownership Interests - Arvinas
Travel, Accommodations, Expenses - Arvinas
 
Marcia Dougan Moore
Employment - Arvinas; Arvinas
Stock and Other Ownership Interests - Arvinas
Research Funding - Arvinas
Travel, Accommodations, Expenses - Arvinas; Arvinas
 
Ronald Alan Peck
Employment - Arvinas; TESARO
Leadership - Arvinas
Stock and Other Ownership Interests - arvinas; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Arvinas; Tesaro
 
Howard A. Burris
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst)
Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kyocera (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo (Inst); Pfizer (Inst)